Join us in-person in Toronto, Canada at HUPO 2025. Learn more about our involvement in the event below.
Evotec at HUPO 2025
Poster Presentation
Next-Generation Chemoproteomics for Covalent Drug Target Identification
Poster Viewing: Poster Session 2
Poster Number: 528
Date and Time: Tuesday, November 11, 2025, 1:15 PM - 3:15 PM
Reactive cysteine residues are attractive targets for covalent drug discovery due to their nucleophilicity and strategic positioning in diverse protein regions. Cysteine Proteomics Profiling (CPP) enables proteome-wide assessment of cysteine ligandability, compound binding, and target engagement in cellular contexts.
At Evotec, we developed two complementary CPP platforms: a live-cell workflow for in cellulo mapping and compound profiling, and a high-throughput lysate-based workflow for fragment screening. These platforms support multiple stages of covalent drug development and were applied to evaluate the engagement of Sulfopin, VVD-133214, and Eltanexor.
Presented by Marie Guillemot, Biochemistry GL Translational Proteomics and Metabolomics
Deep Plasma Proteomics Using Bead-Based Approaches in Combination With LC-MS/MS Analysis: How Is the Next Generation of Technologies Performing?
Poster Viewing: Poster Session 3
Date and Time: Wednesday, Nov 12, 2025, 1:15 PM - 3:15 PM
Over the last years, multiple players in the clinical proteomics field have demonstrated that nano- or microparticles can be used to overcome the dynamic range problem for biofluids like plasma, serum or CSF. Identification of more than 3,000 and up to 7,000 proteins from human plasma is now routinely achieved using technologies such as the Proteograph, ENRICH or Mag-Net. In parallel, the release of the Orbitrap Astral Mass spectrometer in combination with the new Vanquish Tandem LC system, set entirely new limits with respect to speed, sensitivity and robustness of (plasma) proteomics measurements. Here, we analyze the second generation of bead-based technologies, with a focus on the newly released Proteograph ONE kit in the context of high-throughput proteomics for human patient cohort screening.
Presented by Carleen Kluger, GL Clinical Proteomics
